BiotechTube
Epitopoietic Research

Epitopoietic Research

Phase 1
Brussels, BelgiumFounded 2000erc-immunotherapy.com

ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the treatment of patients with Glioblastoma multiforme (GBM) the most deadliest form of brain cancer using its patented Gliovac/ERC1671 vaccine.

Founded
2000
Focus
Cell & Gene TherapyVaccines

About

ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the treatment of patients with Glioblastoma multiforme (GBM) the most deadliest form of brain cancer using its patented Gliovac/ERC1671 vaccine.

Funding History

3

Total raised: $32.5M

Grant$2.5MEuropean CommissionJun 15, 2020
Series B$20MUndisclosedJun 15, 2018
Series A$10MUndisclosedJun 15, 2015

Company Info

TypePrivate
Founded2000
LocationBrussels, Belgium
StagePhase 1

Contact

erc-immunotherapy.com

Sectors

Immunotherapy / Immuno-OncologyOncology (General)Cell & Gene Therapy
SIMILAR COMPANIES
Miracor Medical
Miracor Medical
Pre-clinical · Zaventem
AML Clinical Services
AML Clinical Services
Pre-clinical · Leuven
Anacura
Anacura
Pre-clinical · Ghent
Aseptic Technologies
Aseptic Technologies
Pre-clinical · Gembloux
Aspect Analytics
Aspect Analytics
Pre-clinical · Leuven
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile